Timi Edeki

2.0k total citations
41 papers, 1.6k citations indexed

About

Timi Edeki is a scholar working on Pharmacology, Pharmacology and Epidemiology. According to data from OpenAlex, Timi Edeki has authored 41 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Pharmacology, 11 papers in Pharmacology and 8 papers in Epidemiology. Recurrent topics in Timi Edeki's work include Antibiotics Pharmacokinetics and Efficacy (14 papers), Pharmacogenetics and Drug Metabolism (10 papers) and Pneumonia and Respiratory Infections (7 papers). Timi Edeki is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (14 papers), Pharmacogenetics and Drug Metabolism (10 papers) and Pneumonia and Respiratory Infections (7 papers). Timi Edeki collaborates with scholars based in United States, United Kingdom and Germany. Timi Edeki's co-authors include Nu He, Shampa Das, Joyce A. Goldstein, Patrick Griffith, Robert C. Green, Rodney C.P. Go, Lindsay A. Farrer, David Bachman, L. Adrienne Cupples and Timothy B. Curry and has published in prestigious journals such as Antimicrobial Agents and Chemotherapy, Journal of the American Geriatrics Society and Clinical Pharmacology & Therapeutics.

In The Last Decade

Timi Edeki

41 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Timi Edeki United States 19 450 394 336 271 265 41 1.6k
Jacqueline B. McCrea United States 26 297 0.7× 311 0.8× 81 0.2× 279 1.0× 93 0.4× 77 2.0k
Robert H. Palmer United States 28 827 1.8× 260 0.7× 694 2.1× 750 2.8× 100 0.4× 91 3.0k
H. Friedman United States 24 341 0.8× 227 0.6× 204 0.6× 112 0.4× 85 0.3× 53 1.3k
Nicolas Simon France 31 663 1.5× 141 0.4× 275 0.8× 165 0.6× 69 0.3× 146 2.6k
Steven Troy United States 19 494 1.1× 137 0.3× 218 0.6× 128 0.5× 322 1.2× 49 1.3k
S. A. Kaplan United States 20 465 1.0× 270 0.7× 234 0.7× 219 0.8× 105 0.4× 42 1.7k
Hartmut Derendorf United States 20 417 0.9× 153 0.4× 65 0.2× 133 0.5× 153 0.6× 45 1.7k
Robert E. Weinfeld United States 23 541 1.2× 223 0.6× 301 0.9× 201 0.7× 108 0.4× 34 1.6k
Arthur B. Straughn United States 26 378 0.8× 271 0.7× 460 1.4× 186 0.7× 38 0.1× 71 2.1k
Joseph C. Fleishaker United States 27 462 1.0× 381 1.0× 538 1.6× 212 0.8× 20 0.1× 85 2.1k

Countries citing papers authored by Timi Edeki

Since Specialization
Citations

This map shows the geographic impact of Timi Edeki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Timi Edeki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Timi Edeki more than expected).

Fields of papers citing papers by Timi Edeki

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Timi Edeki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Timi Edeki. The network helps show where Timi Edeki may publish in the future.

Co-authorship network of co-authors of Timi Edeki

This figure shows the co-authorship network connecting the top 25 collaborators of Timi Edeki. A scholar is included among the top collaborators of Timi Edeki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Timi Edeki. Timi Edeki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Nicolau, David P., Leonard Siew, J. Armstrong, et al.. (2015). Phase 1 study assessing the steady-state concentration of ceftazidime and avibactam in plasma and epithelial lining fluid following two dosing regimens. Journal of Antimicrobial Chemotherapy. 70(10). 2862–2869. 106 indexed citations
2.
Li, Jianguo, et al.. (2015). A Randomized, Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of Ceftazidime-Avibactam in Healthy Chinese Subjects. Clinical Drug Investigation. 36(2). 119–126. 11 indexed citations
3.
Edeki, Timi, et al.. (2015). Phase I study assessing the safety, tolerability, and pharmacokinetics of avibactam and ceftazidime–avibactam in healthy Japanese volunteers. Journal of Infection and Chemotherapy. 21(8). 551–558. 31 indexed citations
4.
Vishwanathan, Karthick, Stuart Mair, Anshul Gupta, et al.. (2014). Assessment of the Mass Balance Recovery and Metabolite Profile of Avibactam in Humans and In Vitro Drug-Drug Interaction Potential. Drug Metabolism and Disposition. 42(5). 932–942. 42 indexed citations
5.
Giacomini, Kathleen M., Praveen Balimane, Michael T. Eadon, et al.. (2013). International Transporter Consortium Commentary on Clinically Important Transporter Polymorphisms. Clinical Pharmacology & Therapeutics. 94(1). 23–26. 120 indexed citations
6.
7.
Karara, Adel H., Timi Edeki, James F. McLeod, Alfred Tonelli, & John A. Wagner. (2010). PhRMA Survey on the Conduct of First‐in‐Human Clinical Trials Under Exploratory Investigational New Drug Applications. The Journal of Clinical Pharmacology. 50(4). 380–391. 10 indexed citations
8.
Williams, J. Andrew, Tommy Andersson, Tommy B. Andersson, et al.. (2008). PhRMA White Paper on ADME Pharmacogenomics. The Journal of Clinical Pharmacology. 48(7). 849–889. 37 indexed citations
9.
He, Nu, et al.. (2007). INDUCTION OF CYP3A IN PRIMARY CULTURES OF HUMAN HEPATOCYTES BY GINKGOLIDES A AND B. Clinical and Experimental Pharmacology and Physiology. 34(7). 632–635. 10 indexed citations
10.
He, Nu, et al.. (2006). EFFECTS OF INDIVIDUAL GINSENOSIDES, GINKGOLIDES AND FLAVONOIDS ON CYP2C19 AND CYP2D6 ACTIVITY IN HUMAN LIVER MICROSOMES. Clinical and Experimental Pharmacology and Physiology. 33(9). 813–815. 25 indexed citations
11.
Gustavson, Linda E., David Burt, Ramanuj Achari, et al.. (2006). Evaluation of the potential for pharmacokinetic interaction between fenofibrate and ezetimibe: A phase I, open-label, multiple-dose, three-period crossover study in healthy subjects. Clinical Therapeutics. 28(3). 373–387. 22 indexed citations
12.
Morrow, Jason D., Timi Edeki, Mohamed El Mouelhi, et al.. (2005). American Society for Clinical Pharmacology and Therapeutics Position Statement on Dietary Supplement Safety and Regulation*. Clinical Pharmacology & Therapeutics. 77(3). 113–122. 20 indexed citations
13.
Karyekar, Chetan S., Rajendra Pradhan, Qin Ji, et al.. (2005). A Phase I Multiple‐Dose Escalation Study Characterizing Pharmacokinetics and Safety of ABT‐578 in Healthy Subjects. The Journal of Clinical Pharmacology. 45(8). 910–918. 10 indexed citations
14.
He, Nu & Timi Edeki. (2004). The Inhibitory Effects of Herbal Components on CYP2C9 and CYP3A4 Catalytic Activities in Human Liver Microsomes. American Journal of Therapeutics. 11(3). 206–212. 70 indexed citations
15.
Green, Robert C., L. Adrienne Cupples, A Kurz, et al.. (2003). Depression as a Risk Factor for Alzheimer Disease. Archives of Neurology. 60(5). 753–753. 429 indexed citations
16.
Kidd, Robert S., Timothy B. Curry, Susan Gallagher, et al.. (2001). Identification of a null allele of CYP2C9 in an African–American exhibiting toxicity to phenytoin. Pharmacogenetics. 11(9). 803–808. 196 indexed citations
17.
Edeki, Timi. (1996). Clinical importance of genetic polymorphism of drug oxidation.. PubMed. 63(5-6). 291–300. 12 indexed citations
18.
Edeki, Timi, et al.. (1996). COMPARISON OF PLASMA PROTEIN BINDING OF BASIC DRUGS IN BLACK AND WHITE INDIVIDUALS. American Journal of Therapeutics. 3(9). 611–615. 1 indexed citations
19.
Robin, Deborah W., et al.. (1996). Increased Baseline Sway Contributes to Increased Losses of Balance in Older People Following Triazolam. Journal of the American Geriatrics Society. 44(3). 300–304. 28 indexed citations
20.
Johnston, A. E., et al.. (1990). Tolerability and Kinetics of Intravenous Medifoxamine in Healthy Volunteers. International Clinical Psychopharmacology. 5(2). 97–102. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jacqueline B. McCrea Breakdown of academic impact, for papers by Robert H. Palmer Breakdown of academic impact, for papers by H. Friedman Breakdown of academic impact, for papers by Nicolas Simon Breakdown of academic impact, for papers by Steven Troy Breakdown of academic impact, for papers by S. A. Kaplan Breakdown of academic impact, for papers by Hartmut Derendorf Breakdown of academic impact, for papers by Robert E. Weinfeld Breakdown of academic impact, for papers by Arthur B. Straughn Breakdown of academic impact, for papers by Joseph C. Fleishaker
Rankless by CCL
2026